Cullinan Therapeutics, Inc. (CGEM) vs LB Pharmaceuticals Inc Common Stock (LBRX)
A side-by-side comparison of Cullinan Therapeutics, Inc. and LB Pharmaceuticals Inc Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGEM
Cullinan Therapeutics, Inc.
$17.33HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
LBRX
LB Pharmaceuticals Inc Common Stock
$35.08HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT
Total return — CGEM vs LBRX
growth of $100 · dividends reinvested · last 1yCGEM +147.9% (+147.9%/yr)LBRX +100.1% (+100.1%/yr)CGEM compounded faster over this window
CGEM LBRX
CGEM vs LBRX: by the numbers
- •CGEM is the larger company ($1.06B vs $1.01B market cap).
Metrics side by side
Valuation
| Metric | CGEM | LBRX |
|---|---|---|
| P/B ratio | 3.31 | 3.03 |
Profitability
| Metric | CGEM | LBRX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -63.62% | -25.78% |
| ROIC | -68.64% | -28.14% |
Growth (annualized)
| Metric | CGEM | LBRX |
|---|---|---|
| Total return CAGR (5Y) | -7.48% | N/A |
Go deeper
Dig into the metrics
Cullinan Therapeutics ROELB Pharmaceuticals Inc Common Stock ROECullinan Therapeutics operating marginLB Pharmaceuticals Inc Common Stock operating marginCullinan Therapeutics revenue growthLB Pharmaceuticals Inc Common Stock revenue growthCullinan Therapeutics free cash flowLB Pharmaceuticals Inc Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.